Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

April 7, 2022

Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference

March 10, 2022

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 7, 2022

Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

March 2, 2022

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

February 9, 2022

Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

January 11, 2022

Harpoon Therapeutics Provides Pipeline Development Milestones for 2022

December 13, 2021

Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms

December 11, 2021

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

December 7, 2021

Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021

November 12, 2021

Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2022. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations